Louise Chen
Stock Analyst at Scotiabank
(3.54)
# 790
Out of 5,182 analysts
293
Total ratings
47.74%
Success rate
22.81%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $31.26 | +27.96% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $225.34 | +17.60% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $57.78 | +3.84% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $110.23 | +8.86% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $744.44 | +3.43% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $20.98 | +281.32% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $4.41 | +104.08% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $30.64 | -54.31% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.95 | +515.38% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $23.36 | +135.45% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $69.22 | -20.54% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $4.27 | +251.29% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $128.64 | -61.13% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.99 | +150.42% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $36.61 | -53.56% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $18.04 | +177.16% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $7.95 | +277.36% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $21.88 | +151.37% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.67 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $41.20 | +288.35% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $59.72 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $197.38 | +21.59% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.79 | +67.97% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.81 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.85 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $868.27 | +1.93% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.22 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.62 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.33 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.45 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.25 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.93 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.93 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.49 | +1,762.46% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.45 | +104.08% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.45 | +271.75% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $23.42 | +113.49% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.07 | +141.55% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.64 | +1,309.55% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.28 | +602,463,305.93% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $225.33 | +14.50% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.19 | +4,101.68% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.20 | +1,566.67% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.26 | +755.51% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $31.26
Upside: +27.96%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $225.34
Upside: +17.60%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $57.78
Upside: +3.84%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $110.23
Upside: +8.86%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $744.44
Upside: +3.43%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $20.98
Upside: +281.32%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $4.41
Upside: +104.08%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $30.64
Upside: -54.31%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.95
Upside: +515.38%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $23.36
Upside: +135.45%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $69.22
Upside: -20.54%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.27
Upside: +251.29%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $128.64
Upside: -61.13%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.99
Upside: +150.42%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $36.61
Upside: -53.56%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $18.04
Upside: +177.16%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $7.95
Upside: +277.36%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.88
Upside: +151.37%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.67
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $41.20
Upside: +288.35%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $59.72
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $197.38
Upside: +21.59%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.79
Upside: +67.97%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.81
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.85
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $868.27
Upside: +1.93%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.22
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.62
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.33
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.45
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.25
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.93
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.93
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.49
Upside: +1,762.46%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.45
Upside: +104.08%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.45
Upside: +271.75%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $23.42
Upside: +113.49%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.07
Upside: +141.55%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.64
Upside: +1,309.55%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.28
Upside: +602,463,305.93%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $225.33
Upside: +14.50%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.19
Upside: +4,101.68%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.26
Upside: +755.51%